Impact of Testosterone on Epigenetic regulated of Cellular senescence in Transgender me
- Conditions
- 20 to 40-year-old Transgender men requiring Testosterone treatmentTestosterone, Transgender men, Transmen, Female-to-male, Epigenetics, Sirtuin-1, Alu Methylation, SAM/SAH ratio, Metabolism, Age-related disease
- Registration Number
- TCTR20231014006
- Lead Sponsor
- Ratchasapisek Sompoch grant
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
20 to 40-year-old healthy Transgender men who come to follow up at the Transgender clinic at King Chulalongkorn Memorial Hospital
- Transmen who have not received testosterone
- Transmen who have not undergone sex reassignment surgery or ovarian surgery
- agree to participate in research by signing
- Thai nationality
- able to communicate in Thai
Exclusion Criteria
- Have a history of hormonal disorders
- Have NCDs such as Diabetes, CVD, Cancer, Stroke, Renal failure, Chronic respiratory disease
- Received any drugs known to affect hormone metabolism
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sirtuin-1 expression at 0, 4, 8, 12 weeks after Testosterone treatment ELISA
- Secondary Outcome Measures
Name Time Method Alu methylation at 0, 4, 8, 12 weeks after Testosterone treatment Pyrosequencing,SAM/SAH ratio at 0, 4, 8, 12 weeks after Testosterone treatment ELISA,Metabolic outcome at 0, 12 weeks after Testosterone treatment Blood pressure, CBC, Lipid profile, Liver function test, fasting blood sugar, HbA1C